Baxdela, Quofenix (delafloxacin) is a small molecule pharmaceutical. Delafloxacin was first approved as Baxdela on 2017-06-19. It is used to treat bacterial infections, bacterial skin diseases, escherichia coli infections, klebsiella infections, and staphylococcal infections amongst others in the USA. It has been approved in Europe to treat bacterial skin diseases. Baxdela's patents are valid until 2033-02-27 (FDA).
|Indication||bacterial infections, bacterial skin diseases, escherichia coli infections, klebsiella infections, staphylococcal infections, streptococcal infections|
|Drug Class||Antibacterials (quinolone derivatives)|